Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Recombinant CD19xCD3 Double Antibody (A-319) in the Treatment of Active/Refractory Systemic Lupus Erythematosus

NCT06400537 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT06400537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06400537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Recombinant CD19xCD3 Double Antibody (A-319) in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 1
Overall status
Recruiting
Start date
July 20, 2024
Completion date
December 31, 2026
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus